TY - JOUR
T1 - Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases
AU - van der Pool, Anne E. M.
AU - Marsman, Hendrick A.
AU - Verheij, Joanne
AU - ten Kate, Fibo J.
AU - Eggermont, Alexander M. M.
AU - Ijzermans, Jan N. M.
AU - Verhoef, Cornelis
PY - 2012
Y1 - 2012
N2 - Background: Chemotherapy (CTx) before resection of colorectal liver metastases (CRLM) may cause hepatic injury and postoperative complications. To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications. Methods: Patients with CRLM who received neoadjuvant CTx and underwent resection between 2003 and 2008 were analyzed whether or not they received bevacizumab added to oxaliplatin-based CTx. Results: The total study group existed of 104 patients: 53 patients received oxaliplatin-based CTx and 51 patients received oxaliplatin-based CTx and bevacizumab. The overall complication rate (29%) was not significantly different between the two groups. The bevacizumab group exhibited less moderate sinusoidal dilatation (8% vs. 28%, P = 0.01). No difference in complication rate was found between patients given fewer than six cycles of oxaliplatin-based CTx and those given six or more cycles, or between patients with a short ( <5 weeks) interval between the last dose of oxaliplatin and resection and those in which the interval was longer. Conclusion: Bevacizumab added to oxaliplatin-based CTx may protect against moderate sinusoidal dilatation without significantly influencing morbidity. Neither duration of oxaliplatin-based CTx nor the time interval between cessation of oxaliplatin-based CTx and surgery were associated with postoperative complications. J. Surg. Oncol. 2012; 106:892897. (C) 2012 Wiley Periodicals, Inc
AB - Background: Chemotherapy (CTx) before resection of colorectal liver metastases (CRLM) may cause hepatic injury and postoperative complications. To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications. Methods: Patients with CRLM who received neoadjuvant CTx and underwent resection between 2003 and 2008 were analyzed whether or not they received bevacizumab added to oxaliplatin-based CTx. Results: The total study group existed of 104 patients: 53 patients received oxaliplatin-based CTx and 51 patients received oxaliplatin-based CTx and bevacizumab. The overall complication rate (29%) was not significantly different between the two groups. The bevacizumab group exhibited less moderate sinusoidal dilatation (8% vs. 28%, P = 0.01). No difference in complication rate was found between patients given fewer than six cycles of oxaliplatin-based CTx and those given six or more cycles, or between patients with a short ( <5 weeks) interval between the last dose of oxaliplatin and resection and those in which the interval was longer. Conclusion: Bevacizumab added to oxaliplatin-based CTx may protect against moderate sinusoidal dilatation without significantly influencing morbidity. Neither duration of oxaliplatin-based CTx nor the time interval between cessation of oxaliplatin-based CTx and surgery were associated with postoperative complications. J. Surg. Oncol. 2012; 106:892897. (C) 2012 Wiley Periodicals, Inc
U2 - https://doi.org/10.1002/jso.23142
DO - https://doi.org/10.1002/jso.23142
M3 - Article
C2 - 22552819
SN - 0022-4790
VL - 106
SP - 892
EP - 897
JO - Journal of surgical oncology
JF - Journal of surgical oncology
IS - 7
ER -